Pediatric Radiation Oncology in the Era of COVID‐19: A Single Institution Analysis

TL;DR

This study examines how the COVID-19 pandemic affected rural pediatric cancer patients' access to radiation therapy, finding increased rural travel and specific cancer types post-pandemic.

Contribution

The study provides new insights into the impact of the pandemic on rural pediatric oncology care and highlights disparities in radiation therapy access.

Findings

Post-COVID, more rural patients traveled for radiation therapy, with a 4.5x increase from rural counties.

Patients post-COVID had higher rates of central nervous system and non-hematologic cancers.

No significant differences were found in race, age, distance traveled, or treatment costs between pre- and post-COVID groups.

Abstract

As a result of the COVID‐19 pandemic, health inequities have garnered heightened attention in the public consciousness. In particular, rural access to diagnosis and radiotherapy (RT) for pediatric oncology patients was markedly affected during this period. The fractionated nature of RT creates a transportation burden for this population. We reviewed our institutional experience with pediatric oncologic therapy at a tertiary academic center serving a primarily rural population over a large geographic area.

Pediatric patients aged ≤ 18 years diagnosed with cancer between 2018 and 2022 at our institution were investigated, and we identified the subset of patients who received RT at our institution. Patients were categorized as pre‐COVID onset (diagnosed between 2018 and January 31, 2020) or post‐COVID onset (diagnosed on or after January 31, 2020, to December 1st, 2022). Chi‐Square and Student's t‐tests were used to elucidate associations between patient demographics and treatment modalities in the pre‐ and post‐COVID onset groups.

A total of 114 patients were identified. For patients that received RT (n = 22), 4.5 times more patients traveled from rural counties post‐COVID onset (p = 0.027). These patients also saw increased rates of central nervous system (CNS) and non‐hematologic cancer diagnosis (p = 0.013 and 0.049, respectively). No difference was seen concerning race, patient age, or average distance traveled (p = 0.371, 0.249, and 0.420, respectively). No difference was seen in the estimated transportation cost incurred as a result of RT treatment (p = 0.144) or in treatment with concurrent chemotherapy (p = 0.245). For the entire cohort, no associations were seen concerning age, race, rural versus urban home county, cancer primary site, or in the prevalence of hematologic‐ or CNS‐based cancers.

Our results highlight the importance of understanding barriers to care to improve outcomes in rural pediatric patients, as the burden of RT may be greater for these patients than for those living in urban counties. Further investigation into barriers to treatment among rural pediatric patients undergoing RT is warranted.

Figures